In the latest trading session, 0.45 million Larimar Therapeutics Inc (NASDAQ:LRMR) shares changed hands as the company’s beta touched 0.83. With the company’s most recent per share price at $6.24 changing hands around $0.04 or 0.65% at last look, the market valuation stands at $398.15M. LRMR’s current price is a discount, trading about -119.23% off its 52-week high of $13.68. The share price had its 52-week low at $3.34, which suggests the last value was 46.47% up since then. When we look at Larimar Therapeutics Inc’s average trading volume, we note the 10-day average is 0.67 million shares, with the 3-month average coming to 748.60K.

Analysts gave the Larimar Therapeutics Inc (LRMR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.09. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LRMR as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Larimar Therapeutics Inc’s EPS for the current quarter is expected to be -0.32.

Larimar Therapeutics Inc (NASDAQ:LRMR) trade information

Instantly LRMR is in green as seen in intraday trades today. With action -1.42%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 37.14%, with the 5-day performance at -1.42% in the red. However, in the 30-day time frame, Larimar Therapeutics Inc (NASDAQ:LRMR) is -19.38% down. Looking at the short shares, we see there were 3.31 million shares sold at short interest cover period of 4.49 days.

The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 71.64% from its recent market value. According to analyst projections, LRMR’s forecast low is 14 with 25 as the target high. To hit the forecast high, the stock’s price needs a -300.64% plunge from its current level, while the stock would need to soar -124.36% for it to hit the projected low.

Larimar Therapeutics Inc (LRMR) estimates and forecasts

Data shows that the Larimar Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -34.38% over the past 6 months, a -38.10% in annual growth rate that is considerably lower than the industry average of 16.60%.

According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 48.33%. The 2024 estimates are for Larimar Therapeutics Inc earnings to decrease by -41.50%.

LRMR Dividends

Larimar Therapeutics Inc is expected to release its next quarterly earnings report in January.

Larimar Therapeutics Inc (NASDAQ:LRMR)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.45% of Larimar Therapeutics Inc shares while 106.58% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 108.15%. There are 106.58% institutions holding the Larimar Therapeutics Inc stock share, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) the top institutional holder. As of 2024-06-30, the company held 39.6461% of the shares, roughly 21.23 million LRMR shares worth $153.93 million.

RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 11.2884% or 6.05 million shares worth $43.83 million as of 2024-06-30.

Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.34 shares estimated at $8.39 million under it, the former controlled 2.10% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.79% of the shares, roughly 1.14 shares worth around $7.12 million.